MimiVax is a privately held, clinical-stage biotech company founded in 2012 with funding from the Roswell Park Comprehensive Cancer Center.

MimiVax has raised nearly $25 million from Buffalo Capital Partners, Varia Ventures, Fosun Pharma, the National Brain Tumor Society, the Sontag Foundation, MEDA Angels, Tech coast Angels, Private Investors and Roswell Park. All funds are directed to support our clinical programs.

Immuno-oncology is a challenging and unexplored area, but MimiVax has rapidly grown its pipeline and flagship product, SurVaxM, with both investor support and donations to Roswell Park. 

The costs associated with developing and bringing vaccines to market are historically high, and MimiVax fully recognizes the importance of funding sources to continue developing breakthrough therapies so we with investors work with pharmaceutical companies interested in partnership-sponsored trials.

MimiVax is working to improve outcomes and quality of life for those suffering from devastating disease, but it is also strengthening the biomedical startup ecosystem in Buffalo, New York and the Buffalo Niagara Medical Campus. The initial success of MimiVax has attracted positive national and international attention while building confidence in Western New York’s ability to develop locally produced research into commercial development.

If you are an investor interested in MimiVax, please contact us at [email protected]